Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
NCT03445000 · ETOP IBCSG Partners Foundation · PHASE2 · terminated · last registry update 2026-07-21 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment rate” | Open Targets' class: insufficient enrollment | Registry record, ETOP IBCSG Partners Foundation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-11Phase 3 first posted: Guangzhou JOYO Pharma Co., Ltd, JYP0322 Tablets + Crizotinib Capsules (NCT07816380)
- 2026-04-30Results posted on the registry: Xcovery Holdings, Inc., Phase I: X-396 (ensartinib) + Phase II: X-396 (ensartinib) (NCT01625234)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision